Pediatric Cancer Survivors Have 4-Fold Higher Risk of Death 40 Years After Diagnosis
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.
Children prescribed a medication containing a phthalate had a 19% higher risk of developing any childhood cancer.
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
Less than 10% of radiotherapy recommendations in 2020 NCCN guidelines were category 1 recommendations.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.